Akesobio IPO: Valuation Insights
Akeso Biopharma Inc (9926 HK) is a clinical-stage biopharmaceutical company with aims to address global unmet medical needs in oncology, immunology...
550 Views
Akesobio (康方生物) IPO: Expect near Zero Allocation
Akesobio launched book building to raise up to USD 333 million to list in Hong Kong. In our previous note, we discussed that the company features...
715 Views
Akesobio IPO Initiation: The Tough Get Going
Akeso Biopharma Inc (1495016D CH) is a clinical-stage biopharmaceutical company with aims to address global unmet medical needs in oncology,...
556 Views
Akesobio (康方生物) Pre-IPO: Clinical Trial Updates from PHIP
Akesobio is a clinical-stage biopharmaceutical company with a focus on developing biologics drugs for oncology and autoimmune. The company plans to...
594 Views
InnoCare Pharma: Trading Debut, Valuation Scenario Analysis
InnoCare Pharma Ltd (9969 HK) is a pre-revenue biotech company with a focus on research and development, manufacturing and commercialisation of...
409 Views